Aksense is a technology company.
Aksense has raised $160K across 1 funding round.
Aksense has raised $160K in total across 1 funding round.
Aksense has raised $160K in total across 1 funding round.
Aksense's investors include Foundry Group, SOSV, Spark Capital, Will Herman.
Aksense is a biotech startup developing the first portable diagnostics biosensor for rapid detection of healthcare-associated infections (HAIs), delivering results in minutes rather than days.[2][3][4] It serves hospitals and healthcare providers by addressing HAIs—a global crisis causing millions of extra hospital days and deaths annually—through blood-based electrochemical sensing technology with over 90% accuracy, enabling precise antibiotic treatment, cost savings, and lives saved.[2][4] The company is in the prototype stage, focusing on validation, scaling, certification, and securing funding or partnerships.[4]
Aksense emerged from an experienced team of scientists and entrepreneurs in the biotech space, originating in Turkey with a current team of about 5 people.[2][4] The idea stemmed from the critical gap in HAI diagnostics: current lab-based methods take 24-48 hours or up to three days, forcing blind antibiotic prescriptions amid poor hand hygiene compliance (less than half the required times) and rising antimicrobial resistance projected to cause 10 million deaths by 2050.[2][4] A pivotal moment came through the UK-based SETsquared LIF+ programme, where founder Dr. Asiye Karakullukcu refined the business plan, gained an entrepreneurial mindset, identified funding routes, and pitched to investors, transforming a working prototype into a path toward commercialization.[4]
(Note: "Akusense" from search result [1] appears to be a distinct industrial sensor manufacturer unrelated to Aksense's biotech focus.[1])
Aksense rides the wave of point-of-care diagnostics and antimicrobial resistance (AMR) combat, aligning with WHO and CDC priorities amid HAIs causing 147,000 European deaths yearly and global AMR threats.[2] Timing is ideal as biotech advances in electrochemical sensing meet post-pandemic demands for rapid, decentralized testing, fueled by market forces like rising healthcare costs from prolonged hospital stays (16 million extra days in Europe) and regulatory pushes for faster diagnostics.[2][4] It influences the ecosystem by pioneering portable biosensors, potentially accelerating adoption in resource-limited settings, inspiring similar innovations, and supporting grants/partnerships in the UK-Turkey corridor.[4]
Aksense is poised to disrupt HAI management by commercializing its prototype post-validation and certification, targeting funding, UK collaborations, or grants to scale production.[4] Trends like AI-enhanced biotech, global AMR initiatives, and portable medtech growth will propel it, evolving its influence from niche innovator to key player in hospital infection control—ultimately turning minutes-long diagnoses into a standard that saves lives and curbs resistance, fulfilling its life-saving mission from day one.[2]
Aksense has raised $160K across 1 funding round. Most recently, it raised $160K Seed in October 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2019 | $160K Seed | Foundry Group, SOSV, Spark Capital, Will Herman |